Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

被引：0

作者：

Sonneveld, Pieter ^{[1
]}

Asselbergs, Emilie ^{[1
]}

Zweegman, Sonja ^{[2
]}

Van der Holt, Bronno ^{[3
]}

Kersten, Marie Jose ^{[4
]}

Vellenga, Edo ^{[5
]}

van Marwijk-Kooy, Marinus ^{[6
]}

de Weerdt, Okke ^{[7
]}

Lonergan, Sarah

Lokhorst, Henk ^{[8
]}

机构：

[1] Erasmus MC, Rotterdam, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[3] Erasmus MC, HOVON Data Ctr, Rotterdam, Netherlands

[4] AMC, Amsterdam, Netherlands

[5] Univ Med Ctr Groningen UMCG, Groningen, Netherlands

[6] Isala Clin, Zwolle, Netherlands

[7] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[8] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.333.333

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

333

引用

页数：2

共 50 条

[41] Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients
Crusoe, Edvan de Queiroz
Santos, Juliana
Santos, Allan
Santos, Mariane Melo
Salvino, Marco Aurelio
Adorno, Elisangela
Moura, Alessandro
Fonseca, Cleverson Alves
Queiroz, Sarah
Bomfim, Maria da Gloria
Nicanor, Jamile
Santos, Herbert Henrique
Hungria, Vania
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E145 - E146
[42] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Korde, Neha
Derkach, Andriy
Hultcrantz, Malin
Maclachlan, Kylee H.
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Lesokhin, Alexander
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Hofmeister, Craig C.
Kaufman, Jonathan L.
Nooka, Ajay K.
Usmani, Saad Z.
Lonial, Sagar
Joseph, Nisha S.
BLOOD, 2023, 142
[43] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt, Lisa B.
Tichy, Diana
Besemer, Britta
Haenel, Mathias
Raab, Marc S.
Mann, Christoph
Munder, Markus
Reinhardt, Hans Christian
Nogai, Axel
Goerner, Martin
Ko, Yon-Dschun
de Wit, Maike
Salwender, Hans
Scheid, Christof
Graeven, Ullrich
Peceny, Rudolf
Staib, Peter
Dieing, Annette
Einsele, Hermann
Jauch, Anna
Hundemer, Michael
Zago, Manola
Pozek, Ema
Benner, Axel
Bokemeyer, Carsten
Goldschmidt, Hartmut
Weisel, Katja C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 26 - +
[44] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Tan, Carlyn Rose
Derkach, Andriy
Nemirovsky, David
Ciardiello, Amanda
Diamond, Benjamin
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi
Maclachlan, Kylee
Patel, Dhwani
Lahoud, Oscar B. B.
Landau, Heather J. J.
Chung, David J. J.
Shah, Gunjan L. L.
Scordo, Michael
Giralt, Sergio A. A.
Lesokhin, Alexander
Usmani, Saad Z. Z.
Landgren, Ola
Korde, Neha
BLOOD CANCER JOURNAL, 2023, 13 (01)
[45] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Carlyn Rose Tan
Andriy Derkach
David Nemirovsky
Amanda Ciardiello
Benjamin Diamond
Malin Hultcrantz
Hani Hassoun
Sham Mailankody
Urvi Shah
Kylee Maclachlan
Dhwani Patel
Oscar B. Lahoud
Heather J. Landau
David J. Chung
Gunjan L. Shah
Michael Scordo
Sergio A. Giralt
Alexander Lesokhin
Saad Z. Usmani
Ola Landgren
Neha Korde
Blood Cancer Journal, 13
[46] A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)
Berdeja, Jesus G.
Gregory, Tara K.
Kambhampati, Suman
Anz, Bertrand M., III
Tarantolo, Stefano R.
Meluch, Anthony A.
Matous, Jeffrey V.
BLOOD, 2019, 134
[47] Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.
Korde, Neha
Zingone, Adriana
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Costello, Rene
Yancey, Mary Ann
Mulquin, Marcia
Calvo, Katherine R.
Maric, Irina
Tembhare, Prashant
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane Carol
Choyke, Peter L.
Kurdziel, Karen A.
Steinberg, Seth M.
Raffeld, Mark
Roschewski, Mark J.
Landgren, Ola
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[48] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Mehra, Maneesha
Cote, Sarah
Kampfenkel, Tobias
Nair, Sandhya
BLOOD, 2019, 134
[49] Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison
Sonneveld, Pieter
Mateos, Maria-Victoria
Alegre, Adrian
Facon, Thierry
Hulin, Cyrille
Hashim, Mahmoud
Vincken, Talitha
Kampfenkel, Tobias
Cote, Sarah
Moreau, Philippe
BLOOD, 2019, 134
[50] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Bringhen, Sara
Petrucci, Maria Teresa
Larocca, Alessandra
Conticello, Concetta
Rossi, Davide
Magarotto, Valeria
Musto, Pellegrino
Boccadifuoco, Luana
Offidani, Massimo
Omede, Paola
Gentilini, Fabiana
Ciccone, Giovannino
Benevolo, Giulia
Genuardi, Mariella
Montefusco, Vittorio
Oliva, Stefania
Caravita, Tommaso
Tacchetti, Paola
Boccadoro, Mario
Sonneveld, Pieter
Palumbo, Antonio
BLOOD, 2014, 124 (01) : 63 - 69

← 1 2 3 4 5 →